异基因外周血造血干细胞移植治疗恶性血液病  

ALLOGENIC PERIPHERAL STEM CELL TRANSPLANTATION FOR MALIGNANT HEMATOPATHY

作　　者：钟美佐[1] 陈方平[1] 舒毅刚[1] 徐雅静[1] 欧阳红兵[1] 

机构地区：[1]中南大学湘雅医院血液科,长沙410008

出　　处：《中国现代医学杂志》2002年第6期45-47,共3页China Journal of Modern Medicine

摘　　要：目的 :探讨异基因外周血造血干细胞移植治疗恶性血液病的疗效。方法 :用异基因外周血造血干细胞移植治疗恶性血液病 4例 ,预处理方案用TBI 8- 9Gy(分 2d) +CTX 12 0mg/kg。预防移植物抗缩主病 (GVHD)用CSA +短程MTX。结果 :全部患者移植后重建造血 ,DNA序列分析表明 1个月内移植物植入 ,4例患者均出现不同程度的GVHD ,1例出现Ⅳ度aGVHD ,移植后 2个月死于颅内出血 ,其余 3例仍完全缓解 (CR) ,最长者达 16个月。结论 :ALLO -PBSCT是目前治疗恶性血液病最有效的方法之一 ,防治GVHD仍然是临床移植中的一个重要问题。Objective:To determine the efficacy of Allogeneic peripheral stem cell transplantaion (allo-PBSCT) on malignant hematopathy . Method:Four patients with malignant hematopathy were treated by allo-PBSCT,and the preprocessing used TBI 8～9 GY+CTX 120mg/kg.A Combination of cyclosporine and methotrexate was administered to prevent GVHD.Results:All patients were engrafted and hematopoietic reconstruction was rapid;the success of graft was proved by DNA order analysis in a month,GVHD occurred in four patients; IV GVHD occurred in one patient who died 2 months after transplantation;three patients were of complete remission (CR);one of them existed for 16 months.Conclusions:It is one of the most effective methods to treat malignant hematopathy by allo-PBSCT.It is an important problem in the clinical transplantation to prevent and cure GVHD.

关 键 词：恶性血液病 造血干细胞移植 异基因 疗效 移植抗宿主病 植活证据 

分 类 号：R733.05[医药卫生—肿瘤]